| Literature DB >> 34879272 |
Massimiliano Di Filippo1, Andrea Mancini2, Laura Bellingacci2, Lorenzo Gaetani2, Petra Mazzocchetti2, Teresa Zelante3, Livia La Barbera4, Antonella De Luca3, Michela Tantucci2, Alessandro Tozzi5, Valentina Durante2, Miriam Sciaccaluga2, Alfredo Megaro2, Davide Chiasserini5, Nicola Salvadori2, Viviana Lisetti2, Emilio Portaccio6, Cinzia Costa2, Paola Sarchielli2, Maria Pia Amato7, Lucilla Parnetti2, Maria Teresa Viscomi8, Luigina Romani3, Paolo Calabresi9.
Abstract
Cognitive impairment (CI) is a disabling concomitant of multiple sclerosis (MS) with a complex and controversial pathogenesis. The cytokine interleukin-17A (IL-17A) is involved in the immune pathogenesis of MS, but its possible effects on synaptic function and cognition are still largely unexplored. In this study, we show that the IL-17A receptor (IL-17RA) is highly expressed by hippocampal neurons in the CA1 area and that exposure to IL-17A dose-dependently disrupts hippocampal long-term potentiation (LTP) through the activation of its receptor and p38 mitogen-activated protein kinase (MAPK). During experimental autoimmune encephalomyelitis (EAE), IL-17A overexpression is paralleled by hippocampal LTP dysfunction. An in vivo behavioral analysis shows that visuo-spatial learning abilities are preserved when EAE is induced in mice lacking IL-17A. Overall, this study suggests a key role for the IL-17 axis in the neuro-immune cross-talk occurring in the hippocampal CA1 area and its potential involvement in synaptic dysfunction and MS-related CI.Entities:
Keywords: cognitive impairment; experimental autoimmune encephalomyelitis; hippocampus; inflammation; interleukin-17; multiple sclerosis; neuroimmunology; synaptic plasticity
Mesh:
Substances:
Year: 2021 PMID: 34879272 DOI: 10.1016/j.celrep.2021.110094
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423